Organon Takeover Too Costly and Complicated, Says Merck & Co., Inc.; Merck Plans to Close R&D and Production Line with the Loss of Over 2,000 Jobs

March 7, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Dutch News -- US pharmaceuticals giant Merck turned down an offer for its Organon unit in Oss because it would cost the company $700m more than closing it down, the company told a court hearing on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Job creations Europe

Merck & Co. Organon